Press Release: Rebiotix : Ferring to Present Award-Winning, Real-World Outcomes Analysis for Investigational Microbiota-Based Live Biotherapeutic RBX2660 in Patients with Recurrent C. Difficile Infection and IBD at ACG 2021

Ferring Pharmaceuticals and Rebiotix, a Ferring Company, today announced they will present data from two new retrospective analyses as part of American College of Gastroenterology's Annual Scientific Meeting & Postgraduate Course (ACG 2021). The congress will take place in Las Vegas from October 22 - 27, 2021. Eligibility criteria in CDI clinical trials often are narrowly defined, excluding broader patient populations. The first presentation will explore key health outcomes of RBX2660, an i...